Heart failure with preserved ejection fraction

Annals of Internal Medicine

Volumn 158, Issue 1, 2013, Pages

  Meyer, Theo ^a   Shih, Jeffrey ^a   Aurigemma, Gerard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; FUROSEMIDE; GLUCOSE; ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; METOPROLOL;

AGE; ARTICLE; BLOOD CELL COUNT; BRADYCARDIA; CARDIAC PATIENT; CARDIOLOGIST; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DIET; DISEASE CONTROL; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; EXERCISE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART PRELOAD; HEART RATE; HEART RHYTHM; HOSPITALIZATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTERNET; LIVER FUNCTION TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATIENT CARE; PLASMAPHERESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINUS RHYTHM; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; WEIGHT REDUCTION;

DIASTOLE; HEART FAILURE; HUMANS; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STROKE VOLUME;

EID: 84871903740     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.[PMID: 16855265]
2. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18-28.[PMID: 20685685]
3. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction. Eur Heart J. 2007;28:2539-2550.[PMID: 17428822]
4. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119: 1977-2016.[PMID: 19324967]
5. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-1959.[PMID: 15128895]
6. Stein PK, Tereshchenko L, Domitrovich PP, Kleiger RE, Perez A, Deedwania P. Diastolic dysfunction and autonomic abnormalities in patients with systolic heart failure. Eur J Heart Fail. 2007;9:364-369.[PMID: 17123863]
7. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006-2013; discussion 2014. [PMID: 21555723]
8. Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? [Editorial]. J Am Coll Cardiol. 2003;41:1519-1522.[PMID: 12742292]
9. Udelson JE. Heart failure with preserved ejection fraction. Circulation. 2011;124:e540-e543. [PMID: 22105201]
10. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119: 3070-3077. [PMID: 19506115]
11. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-269.[PMID: 16855266]
12. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med. 2006;166:112-128.[PMID: 16401819]
13. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.[PMID: 12151467]
14. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation. 2009;120:2345-2351.[PMID: 19933936]
15. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46: 1019-1026.[PMID: 16168285]
16. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001; 161:996-1002.[PMID: 11295963]
17. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. Eur Heart J. 2008;29:1377-85.[PMID: 18413309]
18. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med. 2002;5:27-37.[PMID: 11974672]
19. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.[PMID: 430798]
20. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004;351: 1097-105.[PMID: 15356307]
21. Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr Opin Cardiol. 2011;26:562-568.[PMID: 21993357]
22. Zile MR, Gottdiener JS, Hetzel SJ, et al; IPRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124:2491-501.[PMID: 22064591]
23. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.[PMID: 14656957]
24. Piller LB, Baraniuk S, Simpson LM, et al; ALLHAT Collaborative Research Group. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011;124:1811-8.[PMID: 21969009]
25. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association. Medical management of hyperglycaemia in type 2 diabetes mellitus. Diabetologia. 2009;52:17-30.[PMID: 18941734]
26. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356: 1955-64.[PMID: 11130523]
27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.[PMID: 10639539]
28. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.[PMID: 18378519]
29. Davis BR, Kostis JB, Simpson LM, et al; ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118:2259-67.[PMID: 19001024]
30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62.[PMID: 8413456]
31. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-38.[PMID: 8416309]
32. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-9.[PMID: 10675071]
33. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357-63.[PMID: 16009792]
34. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-93.[PMID: 11901053]
35. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202.[PMID: 12517230]
36. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-33.[PMID: 19187853]
37. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-9.[PMID: 21138935]
38. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-95.[PMID: 20543134]
39. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118-21.[PMID: 10790356]
40. Yturralde RF, Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis. 2005;47: 314-9.[PMID: 16003646]
41. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948-54.[PMID: 15820160]
42. Grewal J, McKelvie RS, Persson H, et al. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol. 2008;102:733-7. [PMID: 18773998]
43. Wann LS, Curtis AB, January CT, et al; 2011 Writing Group Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation. Circulation. 2011;123:104-123.[PMID: 21173346]
44. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81.[PMID: 13678871]
45. Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33:1750-7.[PMID: 21821849]
46. Zile MR, Gaasch WH, Anand IS, et al; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circ. 2010;121:1393-405.[PMID: 20231531]
47. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119:e391-479.[PMID: 19324966]
48. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002;288:2981-97.[PMID: 12479763]
49. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-6.[PMID: 12867233]
50. Solomon SD, Janardhanan R, Verma A, et al; Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079-87.[PMID: 17586303]
51. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.[PMID: 12466506]
52. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40.[PMID: 12466507]
53. Olsson LG, Swedberg K, Ducharme A, et al; CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J Am Coll Cardiol. 2006;47:1997-2004.[PMID: 16697316]
54. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403.[PMID: 16864724]
55. Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-83.[PMID: 15575053]
56. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Am Heart J. 2011;162: 966-972.e10.[PMID: 22137068]
57. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-74.[PMID: 21709061].
58. Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study). Accessed at http://clinicaltrials.gov/ct2/show/NCT00763867 on September 4, 2012.
59. USDA/USDHHS. Dietary Guidelines for Americans 2010. Washinngton, DC: US Gov Print Office; 2010.
60. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. 2010;3:659-67.[PMID: 20852060]
61. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-9.[PMID: 9826315]
62. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-55.[PMID: 10362198]
63. Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation. 1990;81:III48-III53.[PMID: 2404638]
64. Gottdiener JS, Mc-Clelland RL, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. Ann Intern Med. 2002;137:631-9.[PMID: 12379062]
65. O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol. 2000;86:863-7.[PMID: 11024402]
66. Persson H, Lonn E, Edner M, et al; Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function. J Am Coll Cardiol. 2007;49:687-94.[PMID: 17291934]
67. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J. 2006;151:444-50.[PMID: 16442912]
68. Hillege HL, Nitsch D, Pfeffer MA, et al; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-8.[PMID: 16461840]
69. Pacing for Heart Failure With Preserved Ejection Fraction. Accessed at (HFpEF) http://clinicaltrials.gov/ct2/show/NCT01045291 on 4 September 2012.